Sodium Phenylbutyrate

CAS 1716-12-7 6 current recordsSmall Molecule

Who holds supplier records for Sodium Phenylbutyrate? 6 organisations hold a current record for Sodium Phenylbutyrate: an active US FDA Type II Drug Master File or a CEP. 2 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (2), United States (2) and Germany (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Sodium Phenylbutyrate: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/sodium-phenylbutyrate

Reading the evidence

  • 6 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 2 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Sodium Phenylbutyrate expires 17 Oct 2036. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (6)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Sodium Phenylbutyrate. Country is the organisation's recorded country, not necessarily the manufacturing site.

India2United States2Germany1Country not recorded for 1
Need Sodium Phenylbutyrate sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (2)

Certificates of Suitability on the EDQM register for Sodium Phenylbutyrate, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
CU CHEMIE UETIKON GMBH LahrDE
CEP 2026-235 - Rev 00
Sodium phenylbutyrate
Oct 2026Inspected Jan 2025
Germany
SRI KRISHNA PHARMACEUTICALS LIMITED HyderabadIN
R0-CEP 2020-082 - Rev 00
Sodium phenylbutyrate
May 2023—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (13 listed products contain Sodium Phenylbutyrate). The latest listed patent expires 17 Oct 2036. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Sodium Phenylbutyrate is a drug used in the treatment of urea cycle disorders, where it acts as an ammonia scavenger to help facilitate the excretion of nitrogen. It is often administered to patients with certain enzyme deficiencies to prevent the accumulation of toxic levels of ammonia in the body.

Chemical identity

IUPAC name
sodium 4-phenylbutanoate
Canonical SMILES
C1=CC=C(C=C1)CCCC(=O)[O-].[Na+]
InChIKey
VPZRWNZGLKXFOE-UHFFFAOYSA-M
Synonyms
Buphenyl API, acer-001, amx0035 component sodium phenylbutyrate, albrioza component sodium phenylbutyrate, ammonaps, buphenyl, nsc-657802, olpruva, pheburane, phenylbutyrate sodium, relyvrio component sodium phenylbutyrate

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Nitrogen Binding Agent
Mechanism of action
Ammonium Ion Binding Activity

Therapeutic areas

Urea Cycle DisordersHepatologyGenetic Disorders

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Sodium Phenylbutyrate?

6 organisations hold an active US FDA Type II Drug Master File or a CEP for Sodium Phenylbutyrate: SRI KRISHNA PHARMACEUTICALS LTD (India), NAVINTA LLC (United States), NEW HORIZON PHARMA US INC (United States), PH HEALTH LTD, STHREE CHEMICALS LLC (India) and CU CHEMIE UETIKON GMBH (Germany). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Sodium Phenylbutyrate Drug Master Files are active?

SRI KRISHNA PHARMACEUTICALS LTD (DMF 19569), NAVINTA LLC (DMF 40965), NEW HORIZON PHARMA US INC (DMF 42498), PH HEALTH LTD (DMF 25560) and STHREE CHEMICALS LLC (DMF 38890). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does Sodium Phenylbutyrate have a European Certificate of Suitability?

Yes. 2 organisations hold a valid CEP for Sodium Phenylbutyrate on the EDQM register, including CU CHEMIE UETIKON GMBH Lahr (DE) and SRI KRISHNA PHARMACEUTICALS LIMITED Hyderabad (IN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Sodium Phenylbutyrate?

Yes. The latest patent listed for an approved US product containing Sodium Phenylbutyrate expires 17 Oct 2036, across 13 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Sodium Phenylbutyrate supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Sodium Phenylbutyrate?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.